Metoprolol-Teva - Instructions For Use, Price, Reviews, Analogues

Table of contents:

Metoprolol-Teva - Instructions For Use, Price, Reviews, Analogues
Metoprolol-Teva - Instructions For Use, Price, Reviews, Analogues

Video: Metoprolol-Teva - Instructions For Use, Price, Reviews, Analogues

Video: Metoprolol-Teva - Instructions For Use, Price, Reviews, Analogues
Video: Metoprolol Side Effects 2023, March


Metoprolol-Teva: instructions for use and reviews

  1. 1. Release form and composition
  2. 2. Pharmacological properties
  3. 3. Indications for use
  4. 4. Contraindications
  5. 5. Method of application and dosage
  6. 6. Side effects
  7. 7. Overdose
  8. 8. Special instructions
  9. 9. Application during pregnancy and lactation
  10. 10. Use in childhood
  1. 11. In case of impaired renal function
  2. 12. For violations of liver function
  3. 13. Use in the elderly
  4. 14. Drug interactions
  5. 15. Analogs
  6. 16. Terms and conditions of storage
  7. 17. Terms of dispensing from pharmacies
  8. 18. Reviews
  9. 19. Price in pharmacies

Latin name: Metoprolol-Teva

ATX code: C07AB02

Active ingredient: metoprolol (Metoprolol)

Producer: Merkle, GmbH (Merckle, GmbH) (Germany)

Description and photo update: 09.10.2019

Prices in pharmacies: from 25 rubles.


Metoprolol-Teva tablets
Metoprolol-Teva tablets

Metoprolol-Teva is a selective β 1 -adrenergic blocker that has antianginal, antihypertensive and antiarrhythmic effects.

Release form and composition

The drug is produced in the form of tablets: biconvex, round, white, engraved "M" on one side of the tablet, on the other - risk [10 pcs. in blisters made of PVC (polyvinyl chloride) film and aluminum foil, 3, 5 or 10 blisters in a cardboard box together with instructions for the use of Metoprolol-Teva].

Composition of one tablet:

  • active ingredient: metoprolol tartrate - 50 or 100 mg;
  • additional substances: colloidal silicon dioxide, corn starch, magnesium stearate, croscarmellose sodium, copovidone, MCC (microcrystalline cellulose).

Pharmacological properties


Metoprolol-Teva is a cardioselective β 1 -adrenoreceptor blocker that does not exhibit internal sympathomimetic activity, has a slight membrane stabilizing effect and has antianginal, antihypertensive and antiarrhythmic effects.

The drug blocks in low doses β 1 -adrenergic receptors of the heart, which causes a decrease in the catecholamine-stimulated formation of cAMP (cyclic adenosine monophosphate) from ATP (adenosine triphosphate), a decrease in the intracellular current of calcium ions, and also produces a negative batmo-, ino-, dromo- and chronotropic effect [decrease in heart rate (heart rate), inhibition of conduction and excitability, decrease in myocardial contractility]. At the beginning of therapy with β 1 -adrenergic blockers (on the first day after oral administration), the total peripheral resistance increases due to the elimination of β 2 stimulation-adrenergic receptors and a reciprocal increase in the activity of α-adrenergic receptors. After 1-3 days, this indicator returns to its original value, in the case of prolonged use - decreases.

The antianginal effect of Metoprolol-Tev is due to a decrease in myocardial sensitivity to the effects of sympathetic innervation and a decrease in myocardial oxygen demand caused by a decrease in heart rate (lengthening diastole and improving myocardial perfusion) and contractility. Taking metoprolol helps to reduce the number and severity of angina attacks, as well as to increase exercise tolerance. Due to an increase in the stretching of the muscle fibers of the ventricles and an increase in the end diastolic pressure in the left ventricle, an increase in myocardial oxygen demand is possible, especially in patients with CHF (chronic heart failure).

The antihypertensive effect of Metoprolol-Teva is provided by the following pharmacological properties of metoprolol:

  • inhibition of the activity of the RAAS (renin-angiotensin-aldosterone system), which is especially important for patients with initial hypersecretion of renin;
  • inhibition of the functions of the central nervous system (central nervous system);
  • decreased cardiac output;
  • decreased renin synthesis;
  • restoration of the sensitivity of the baroreceptors of the aortic arch [in response to a decrease in blood pressure (blood pressure) does not increase their activity] and a decrease in peripheral sympathetic influences.

Metoprolol helps to reduce elevated blood pressure during stress, physical exertion and at rest. The antihypertensive effect develops rapidly (15 minutes after taking the drug, systolic blood pressure decreases, the maximum effect is observed after 2 hours) and lasts 6 hours; diastolic blood pressure changes more slowly (a stable decrease is observed after several weeks of regular use).

The antiarrhythmic effect of Metoprolol-Tev is due to a slowdown in atrioventricular conduction [through the atrioventricular node and along additional paths in the antegrade (to a greater extent) and retrograde (to a lesser extent) directions] and a decrease in the rate of spontaneous excitation of ectopic and sinus pacemakers, elimination of the increased content of arrhythmogenic factors (cAMP, tachycardia, arterial hypertension, increased activity of the sympathetic nervous system).

Prevents the development of migraines. With atrial fibrillation, sinus or supraventricular tachycardia, hyperthyroidism and functional heart disease, it slows down the heart rate or even helps to restore sinus rhythm.

Metoprolol, used in moderate therapeutic doses, has a less pronounced (unlike non-selective β-blockers) effect on carbohydrate metabolism and organs containing β 2 -adrenergic receptors (smooth muscles of the uterus, peripheral arteries and bronchi, skeletal muscles, pancreas).

The use of Metoprolol-Teva in large doses (over 100 mg per day) can have a blocking effect on both subtypes of β-adrenergic receptors.


Pharmacokinetic characteristics of metoprolol:

  • absorption: when taken orally, it is absorbed from the gastrointestinal tract (gastrointestinal tract) almost in full - about 95%. Systemic bioavailability is approximately 35%, since metoprolol undergoes intensive first-pass metabolism. C max (maximum concentration) in blood plasma is reached after 1.5–2 hours from the time of administration;
  • distribution: connection with blood proteins - 10%. V d (volume of distribution) - 5.5 l / kg. Penetrates the placental and blood-brain barriers. In small amounts it is excreted in breast milk;
  • metabolism: metoprolol is almost completely metabolized in the liver, mainly with the participation of the isoenzyme CYP2D6. T 1/2 (half-life) - 3-4 hours, however, in patients with a reduced rate of biotransformation of drugs (slow metabolizers) can increase up to 7-8 hours. The metabolites of the active substance - o-desmethylmetoprolol and α-hydroxymetoprolol - exhibit weak β-adrenergic blocking activity;
  • excretion: excreted mainly in the urine - about 95%, about 10% is excreted unchanged. It is not removed by hemodialysis.

In patients with portocaval anastomosis and liver cirrhosis, the bioavailability of metoprolol increases, and the clearance decreases. Thus, in patients with portocaval anastomosis, it is possible to increase the AUC (area under the concentration-time curve) by 6 times and decrease the clearance to 0.3 ml / min.

Indications for use

  • arterial hypertension - monotherapy or combined use with other antihypertensive drugs;
  • hyperthyroidism - complex therapy;
  • functional disorders of cardiac activity, accompanied by tachycardia;
  • heart rhythm disturbances: ventricular extrasystole, supraventricular tachycardia;
  • Ischemic heart disease (coronary artery disease): angina attacks - prevention; myocardial infarction - secondary prevention / combination therapy;
  • migraine attacks - prevention.



  • cardiogenic shock;
  • sinoatrial blockade;
  • atrioventricular block II – III degree (without an artificial pacemaker);
  • SSSU (sick sinus syndrome);
  • severe bradycardia (heart rate less than 50 beats per minute);
  • Prinzmetal's angina;
  • CHF in the stage of decompensation;
  • acute myocardial infarction (heart rate less than 45 beats per minute, PQ interval more than 0.24 seconds or systolic blood pressure less than 100 mm Hg);
  • arterial hypotension (when used for the secondary prevention of myocardial infarction - systolic blood pressure less than 100 mm Hg. Art.);
  • severe forms of bronchial asthma and COPD (chronic obstructive pulmonary disease);
  • COPD in the acute stage;
  • metabolic acidosis;
  • severe disorders of peripheral circulation;
  • pheochromocytoma (without the combined use of α-blockers);
  • lactation;
  • age under 18 years (the safety and efficacy of metoprolol have not been established);
  • long-term or intermittent therapy with inotropic agents that affect β-adrenergic receptors;
  • combined use with MAO (monoamine oxidase) inhibitors;
  • simultaneous intravenous (intravenous) administration of BMCC (slow calcium channel blockers), such as verapamil;
  • hypersensitivity to metoprolol or auxiliary components of the drug, β-blockers.

Relative (Metoprolol-Teva is taken with precautions):

  • impaired renal function [CC (creatinine clearance) less than 40 ml / min];
  • impaired liver function;
  • peripheral circulatory disorders (Raynaud's syndrome, intermittent claudication);
  • atrioventricular block I degree;
  • metabolic acidosis;
  • diabetes;
  • thyrotoxicosis;
  • myasthenia gravis;
  • depression (including history);
  • psoriasis;
  • bronchial asthma;
  • COPD;
  • aggravated allergological history (a decrease in the therapeutic response to epinephrine, an increase in sensitivity to allergens, the transition of arterial hypertension to a more severe form are possible);
  • pregnancy (provided that the expected benefits exceed the possible risks);
  • elderly age.

Metoprolol-Teva, instructions for use: method and dosage

Metoprolol-Teva tablets are taken orally during or immediately after a meal with a liquid. They can be halved by risk, but not chewed.

Recommended dosage regimen:

  • arterial hypertension: initial dose - 50-100 mg 1-2 times a day (morning / evening). If the therapeutic effect is insufficient, the daily dose can be increased to 100-200 mg or an additional intake of other antihypertensive drugs can be prescribed. The maximum daily dose should not exceed 200 mg;
  • functional disorders of cardiac activity, accompanied by tachycardia: 50 mg 2 times a day (morning / evening);
  • arrhythmia, prevention of migraine attacks and angina pectoris: 100-200 mg 1-2 times a day (morning / evening);
  • secondary prevention of myocardial infarction: 100 mg 2 times a day (morning / evening);
  • hyperthyroidism: 50 mg 3-4 times a day.

In elderly patients, the initial dose of Metoprolol-Teva is 50 mg per day.

There is no need to adjust the dose for patients with impaired renal function.

Patients with impaired hepatic function may require dose adjustment of Metoprolol-Teva, depending on their clinical condition.

If it is necessary to interrupt the treatment or to completely stop the drug therapy after its long-term use, it is necessary to gradually, at least over 2 weeks, reduce the dose of metoprolol by 2 times. A gradual decrease in the daily dose will help alleviate the manifestations of the withdrawal syndrome. With a sharp cessation of therapy, myocardial ischemia, exacerbation of angina pectoris, myocardial infarction, as well as increased arterial hypertension are possible.

Side effects

The classification of the incidence of side effects of Metoprolol-Teva is carried out in accordance with the recommendations of the WHO (World Health Organization): very often - not less than 10%; often - not less than 1% and not more than 10%; infrequently - not less than 0.1% and not more than 1%; rarely - not less than 0.01% and not more than 0.1%; very rarely - less than 0.01%:

  • cardiovascular system: often - bradycardia, palpitations, coldness of the lower extremities, orthostatic hypotension (dizziness, loss of consciousness); infrequently - pericardial pain, 1st degree atrioventricular block; rarely - a violation of atrioventricular conduction or worsening of heart failure with peripheral edema and / or shortness of breath during exertion, a marked decrease in blood pressure, increased complaints in patients with peripheral circulation disorders, including patients with Raynaud's syndrome; very rarely - increased seizures in patients with angina pectoris;
  • blood and lymphatic system: very rarely - leukopenia, thrombocytopenia;
  • CNS: often - dizziness, headache, fatigue; infrequently - paresthesias, nervousness, anxiety, slowing down of the speed of mental and motor reactions, asthenic syndrome, cramps in the limbs (in patients with Raynaud's syndrome and intermittent claudication), muscle weakness, decreased attention, sleep disturbances, drowsiness, more frequent and / or brighter dreams, nightmares, confusion, anxiety, depression; very rarely - short-term memory impairment, emotional lability;
  • immune system: rarely - anaphylactic reactions;
  • endocrine system: rarely - masking the symptoms of thyrotoxicosis, hyper-, hypoglycemia in patients with type 1 diabetes mellitus;
  • respiratory system, organs of the chest and mediastinum: often - shortness of breath in patients predisposed to the development of bronchospasm; infrequently - shortness of breath when prescribing large doses (loss of selectivity) and / or in predisposed patients, nasal congestion; rarely - allergic rhinitis;
  • metabolism and nutrition: infrequently - increased body weight; rarely - aggravation of the course of latent diabetes mellitus;
  • Gastrointestinal tract: often - abdominal pain, constipation, diarrhea, nausea, vomiting; infrequently - dryness of the oral mucosa; rarely - a violation of taste;
  • liver and biliary tract: rarely - increased activity of hepatic transaminases; very rarely - hepatitis;
  • skin and subcutaneous tissues: infrequently - increased sweating, pruritus, skin flushing; rarely - alopecia; very rarely - paradoxical psoriasiform inflammatory reaction, photosensitization reaction;
  • musculoskeletal and connective tissue: infrequently - muscle spasm; very rarely - muscle weakness, arthralgia;
  • genitals and mammary gland: rarely - Peyronie's disease, decreased potency, weakened libido;
  • organ of vision: rarely - blurred vision, conjunctivitis, decreased secretion of lacrimal fluid;
  • organ of hearing and labyrinth disorders: rarely - hearing impairment and tinnitus;
  • laboratory indicators: very rarely - an increase in triglyceride levels and a decrease in high-density cholesterol in blood plasma.


An overdose of the drug Metoprolol-Teva is accompanied by the following symptoms: nausea, vomiting, dizziness, cyanosis, severe sinus bradycardia, marked decrease in blood pressure, ventricular premature beats, arrhythmia, bronchospasm, fainting. Symptoms of acute overdose are cardiogenic shock, hyperkalemia, hypoglycemia, angina pectoris, atrioventricular block (up to the development of complete transverse blockade and cardiac arrest), convulsions, loss of consciousness, coma, respiratory arrest.

The first signs of intoxication appear 20–120 minutes after taking high doses of the drug. In case of an overdose or a threatening decrease in heart rate and / or blood pressure, Metoprolol-Teva must be urgently canceled.

Therapy of the condition consists in washing the stomach and taking adsorbing agents, further treatment of symptoms is indicated. With a pronounced decrease in blood pressure, the patient should be given the Trendelenburg position (lying on his back with the pelvis raised at an angle of 45 ° in relation to the head). With a strong decrease in blood pressure, bradycardia and heart failure, β-adrenomimetics are administered intravenously at intervals of 2 to 5 minutes until the desired effect is achieved, or 0.5–2 mg of atropine. If it is not possible to achieve positive dynamics, dobutamine, dopamine or norepinephrine (norepinephrine) are used.

In the case of the development of bronchospasm, β 2 -adrenomimetics are used (intravenous administration), when seizures appear, diazepam is used (intravenous slow administration).

Hemodialysis is ineffective.

special instructions

Patients undergoing desensitizing therapy, and patients with a history of severe hypersensitivity reactions, are at risk due to the risk of severe anaphylactic reactions, since β-adrenergic receptor blockers increase sensitivity to allergens and the severity of anaphylactic reactions.

The use of β-adrenergic receptor blockers in severe impairment of renal function led in some cases to its deterioration. If drug therapy in patients of this category is justified, it must be accompanied by appropriate monitoring of renal function.

During therapy with β-blockers, blood pressure and heart rate should be monitored regularly. Persons with diabetes mellitus require monitoring of blood glucose concentration (at least once every 4–5 months). If necessary, the dose of insulin or hypoglycemic agents administered by mouth for the treatment of diabetes mellitus must be selected individually.

It is necessary to teach the patient how to calculate the heart rate and instruct on the need to see a doctor when the heart rate is less than 50 beats per minute. At a dose of more than 100 mg per day, cardioselectivity decreases.

Patients with heart failure should take Metoprolol-Teva only after reaching the stage of compensation.

Abrupt discontinuation of the drug is unacceptable. Withdrawal should be carried out for at least 14 days, gradually reducing the dose in several doses until it reaches the final minimum of 25 mg once a day.

If during therapy with the drug there is a need for surgical intervention, the surgeon / anesthesiologist should be warned about the use of metoprolol. This will allow the specialist to select a remedy for general anesthesia with a minimal negative lyotropic effect; it is not required to cancel Metoprolol-Teva before the operation. Elimination of reciprocal activation of the vagus nerve is performed by intravenous administration of atropine in a dose of 1–2 mg.

During treatment, symptoms of impaired peripheral arterial circulation may increase.

With angina pectoris, the selected dose of the drug should provide a resting heart rate within 55-60 beats per minute, with a load - no more than 110 beats per minute.

When using contact lenses, it is important to take into account the decrease in tear fluid production during therapy with β-blockers.

The use of the drug masks some of the clinical manifestations of thyrotoxicosis, such as tachycardia. Symptoms in patients with thyrotoxicosis may increase with abrupt withdrawal of Metoprolol-Teva, therefore, they should stop therapy gradually, gradually reducing the daily dose of metoprolol.

In patients with diabetes mellitus, the drug can mask tachycardia caused by hypoglycemia. Metoprolol, in contrast to nonselective β-blockers, has a significantly lesser effect on insulin-induced hypoglycemia and does not delay the restoration of blood glucose concentration to normal levels.

Patients with pheochromocytoma, when they are prescribed the drug Metoprolol-Teva, use α-adrenergic blockers as concomitant therapy, patients with bronchial asthma - β 2 -adrenomimetics.

Reserpine and other drugs that reduce the supply of catecholamines can enhance the effect of β-blockers, and therefore patients taking such combinations of drugs need to be under constant medical supervision for bradycardia and an excessive decrease in blood pressure.

The appearance of skin rashes when taking β-blockers, including Metoprolol-Teva, is the basis for their cancellation.

In elderly patients, liver function should be monitored regularly. If there is a marked decrease in blood pressure (systolic blood pressure less than 100 mm Hg), increasing bradycardia (heart rate less than 50 beats per minute), ventricular arrhythmias, atrioventricular block, bronchospasm, severe liver dysfunction, the dosage regimen must be adjusted, and in some cases - stop treatment.

Patients with depressive disorders taking Metoprolol-Teva should be under special control. If they develop depression while taking β-blockers, it is necessary to discontinue drug therapy.

When taking the drug, the use of alcoholic beverages is undesirable.

In smokers, the effectiveness of β-blockers is reduced.

Influence on the ability to drive vehicles and complex mechanisms

Patients undergoing treatment with the drug should be careful when driving and engaging in other potentially hazardous activities that require speed of psychomotor reactions and high concentration of attention.

Application during pregnancy and lactation

For patients carrying a child, Metoprolol-Teva can be prescribed only on strict indications and only if the intended benefit to the mother exceeds the potential risk to the fetus. Special precautions when taking the drug are associated with the possible development of arterial hypotension, bradycardia or hypoglycemia in the fetus. β-blockers can reduce the permeability of the placenta, which can cause intrauterine fetal death or premature birth.

In newborns exposed to intrauterine exposure to metoprolol, the risk of pulmonary or cardiac complications increases during the postpartum period. You must stop taking the drug 2-3 days before the expected date of birth. If for any reason it is impossible to do this, you should ensure careful medical supervision of newborns during the first 2-3 days from the moment of birth.

Metoprolol passes into breast milk. If the use of the drug during lactation is justified, the infant is transferred to artificial feeding.

Pediatric use

For children and adolescents under the age of 18, Metoprolol-Teva is contraindicated, since there is no information about its safe and effective use in pediatrics.

With impaired renal function

Patients with impaired renal function (CC less than 40 ml / min) should take Metoprolol-Teva with caution.

There is no need to adjust the dose in the presence of impaired renal function.

For violations of liver function

Patients with impaired hepatic function should take Metoprolol-Teva tablets with caution.

In case of impaired liver function, dose adjustment may be required depending on the clinical condition of the patient.

Use in the elderly

In old age, Metoprolol-Teva should be taken with caution. In patients of this group, the initial dose of the drug should not exceed 50 mg per day.

Drug interactions

  • MAO (monoamine oxidase) inhibitors: significantly enhance the antihypertensive effect of Metoprolol-Teva, combined use is not recommended; between taking metoprolol and MAO inhibitors, it is necessary to maintain a break of at least 2 weeks;
  • hypoglycemic agents for oral administration: may decrease their effect; with simultaneous use with insulin, the risk of hypoglycemia increases, its duration and severity increase, some symptoms of hypoglycemia are masked, such as hyperhidrosis, tachycardia, increased blood pressure;
  • antihypertensive drugs, diuretics, nitroglycerin, ACE (angiotensin converting enzyme) inhibitors or slow calcium channel blockers: a significant decrease in blood pressure is possible (special caution should be exercised when combined with prazosin);
  • drugs that inhibit or induce CYP2D6: affect the level of metoprolol in plasma. When combined with drugs that are a substrate for CYP2D6, including antiarrhythmic and antihistamines, antidepressants [SSRIs (selective serotonin reuptake inhibitors), such as paroxetine, fluoxetine, sertraline], H 2 receptor antagonists, cyclooxygenase inhibitors 2 and, the concentration of metoprolol in plasma may increase;
  • antiarrhythmic drugs of the first class: in patients with impaired left ventricular function, it is possible to add a negative inotropic effect with the development of pronounced hemodynamic side effects (people with impaired atrioventricular conduction and CVS should avoid this combination);
  • estrogens that cause sodium ion retention, β-adrenostimulants, cocaine, theophylline, glucocorticoids, indomethacin and other NSAIDs (non-steroidal anti-inflammatory drugs) that cause sodium ion retention and blocking of prostaglandin synthesis by the kidneys: weaken the antihypertensive effect of Metoprolol-Teva;
  • verapamil, reserpine, diltiazem, clonidine, methyldopa, guanfacine and cardiac glycosides, agents for general anesthesia: along with antihypertensive and cardiodepressive effects, a pronounced decrease in heart rate and inhibition of atrioventricular conduction up to complete blockade are possible;
  • quinidine: inhibits the metabolism of metoprolol in fast metabolizers, resulting in an increase in the β-adrenergic blocking effect of metoprolol due to a significant increase in its concentration in plasma;
  • amiodarone: the risk of developing severe sinus bradycardia increases (due to prolonged T 1/2 of amiodarone, this risk persists for a long time after its withdrawal);
  • clonidine: when taken in combination with metoprolol, clonidine must be withdrawn after a few days to avoid the occurrence of withdrawal syndrome;
  • mefloquine: the risk of bradycardia increases;
  • epinephrine: bradycardia and a marked decrease in blood pressure are possible;
  • rifampicin, barbiturates and other inducers of liver microsomal enzymes: increase the metabolism of metoprolol, reduce its concentration in blood plasma, thereby reducing the effect of the drug;
  • oral contraceptives, cimetidine, phenothiazines and other inhibitors of microsomal liver enzymes: increase the concentration of metoprolol in blood plasma;
  • diphenhydramine: enhances the effect of metoprolol, reducing its clearance;
  • phenylpropanolamine (in high doses): a paradoxical increase in blood pressure is possible (up to a hypertensive crisis);
  • lidocaine: metoprolol reduces the clearance of lidocaine, increasing its concentration in blood plasma;
  • allergen extracts for skin tests or allergens used for immunotherapy: increase the risk of anaphylaxis or systemic allergic reactions; when using the drug with iodine-containing X-ray contrast agents for intravenous administration, the risk of anaphylactic reactions increases;
  • xanthine (except diphylline): metoprolol reduces its clearance, especially with an initially increased clearance of theophylline under the influence of smoking;
  • antidepolarizing muscle relaxants: metoprolol prolongs and enhances their effect;
  • coumarins: when combined with metoprolol, the anticoagulant effect of coumarins is enhanced;
  • anxiolytics and drugs with a hypnotic effect: the antihypertensive effect of metoprolol is enhanced;
  • ergot alkaloids: there is an increase in the risk of peripheral circulatory disorders;
  • aldesleukin: the risk of a pronounced and sharp decrease in blood pressure increases;
  • alprostadil: its effectiveness decreases;
  • ethanol: the inhibitory effect on the central nervous system increases and the risk of a pronounced decrease in blood pressure increases.


Metoprolol-Teva analogs are Betalok, Betalok ZOK, Corvitol 50, Corvitol 100, Metocard, Metocor Adipharm, Metoprolol, Metoprolol Zentiva, Metoprolol Organic, Metoprolol-Akrihin, Metoprolol retard-Akrikhin, Metoprolol-OBL, Ecoprolol-OBL Egilok S, Egilok Retard and others.

Terms and conditions of storage

Keep out of the reach of children. Storage temperature should not exceed 25 ° C.

The shelf life is 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Metoprolol-Teva

In most reviews of Metoprolol-Teva, the combined action drug is characterized on the positive side. Patients indicate that thanks to its reception, it was possible not only to stabilize blood pressure, but also to eliminate pain in the heart. For some of them, the remedy at the same time helped to get rid of migraines, and the effectiveness for the relief of common headaches was low. Most of those who took the drug are satisfied with the result, since in addition to all the advantages, they did not notice the appearance of adverse reactions against the background of the use of Metoprolol-Teva. Also, patients noted the low cost of the drug, its speed and availability in pharmacies.

Among the shortcomings, numerous contraindications for admission, short duration of action and disappearance of the effect after the end of therapy were mentioned. In addition, despite the availability and low price of Metoprolol-Tev, users are advised to take it only under the guidance of a doctor.

Price for Metoprolol-Teva in pharmacies

Price for Metoprolol-Teva per pack of 30 pcs. is 25–32 rubles. (tablets with a dosage of 50 mg) or 34–56 rubles. (tablets with a dosage of 100 mg).

Metoprolol-Teva: prices in online pharmacies

Drug name



Metoprolol-Teva 50 mg tablets 30 pcs.

RUB 25


Metoprolol-Teva tablets 100mg 30 pcs.

42 RUB


Metoprolol-Teva 100 mg tablets 30 pcs.

42 RUB


Anna Kozlova
Anna Kozlova

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Popular by topic